4 results
Primary objectiveTo determine whether aprotinin can reverse the increased postoperative blood loss, induced by dual anti-platelet therapy in elective non-complex cardiac surgery.Secondary objectiveTo determine whether aprotinin reduces transfusion…
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
Phase I partPrimary:* Determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D).Secondary:* Safety and tolerability, * ORR, duration of response (DOR), disease control rate (DCR), progression free survival (PFS) and time to…
The BeyeOMARKER study*s primary aim is to (1) provide proof-of-concept for blood-based biomarkers as a tool for minimally invasive early detection of AD pathology in a diverse population from an alternative clinically relevant setting. Secondly, we…